Amgen Inc. (AMGN) Stock Rating Reaffirmed by Morgan Stanley
Amgen Inc. (NASDAQ:AMGN)‘s stock had its “overweight” rating restated by investment analysts at Morgan Stanley in a report issued on Monday.
Other analysts also recently issued research reports about the stock. Goldman Sachs Group, Inc. (The) dropped their target price on shares of Amgen from $208.00 to $202.00 and set a “conviction-buy” rating for the company in a research report on Monday, March 20th. Vetr raised shares of Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 target price for the company in a research report on Monday, March 27th. Jefferies Group LLC reissued a “hold” rating and set a $180.00 target price on shares of Amgen in a research report on Monday, May 22nd. Cann reissued a “positive” rating and set a $189.00 target price on shares of Amgen in a research report on Wednesday, March 15th. Finally, Leerink Swann reissued a “market perform” rating and set a $161.00 target price on shares of Amgen in a research report on Thursday, June 22nd. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and three have assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $185.65.
Amgen (NASDAQ AMGN) opened at 173.32 on Monday. Amgen has a 52 week low of $133.64 and a 52 week high of $184.21. The stock has a market cap of $127.46 billion, a price-to-earnings ratio of 16.46 and a beta of 1.35. The firm’s 50-day moving average is $162.22 and its 200 day moving average is $162.64.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, beating the Zacks’ consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The company had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the company posted $2.90 EPS. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. On average, equities research analysts expect that Amgen will post $12.43 EPS for the current year.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. M. Kraus & Co raised its stake in Amgen by 8.3% in the second quarter. M. Kraus & Co now owns 2,591 shares of the medical research company’s stock valued at $446,000 after buying an additional 198 shares in the last quarter. Laurel Grove Capital LLC raised its stake in Amgen by 71.9% in the second quarter. Laurel Grove Capital LLC now owns 3,467 shares of the medical research company’s stock valued at $597,000 after buying an additional 1,450 shares in the last quarter. Appleton Partners Inc. MA raised its stake in Amgen by 3.3% in the second quarter. Appleton Partners Inc. MA now owns 17,180 shares of the medical research company’s stock valued at $2,959,000 after buying an additional 550 shares in the last quarter. Portland Global Advisors LLC raised its stake in Amgen by 0.3% in the second quarter. Portland Global Advisors LLC now owns 15,071 shares of the medical research company’s stock valued at $2,596,000 after buying an additional 45 shares in the last quarter. Finally, Johanson Financial Advisors Inc. raised its stake in Amgen by 1.5% in the second quarter. Johanson Financial Advisors Inc. now owns 2,100 shares of the medical research company’s stock valued at $362,000 after buying an additional 32 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.